Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Gross Margin (2022 - 2025)

Historic Gross Margin for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to 73.25%.

  • Indivior Pharmaceuticals' Gross Margin fell 52500.0% to 73.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.42%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 80.56% for FY2024, which is 35200.0% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Gross Margin stood at 73.25%, which was down 52500.0% from 82.78% recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Gross Margin registered a high of 86.62% during Q1 2024, and its lowest value of 73.25% during Q3 2025.
  • Moreover, its 4-year median value for Gross Margin was 82.77% (2022), whereas its average is 81.46%.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -83100bps in 2024, then surged by 92000bps in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' Gross Margin stood at 82.16% in 2022, then increased by 0bps to 82.25% in 2023, then rose by 1bps to 83.22% in 2024, then fell by -12bps to 73.25% in 2025.
  • Its Gross Margin was 73.25% in Q3 2025, compared to 82.78% in Q2 2025 and 83.08% in Q1 2025.